Please provide your email address to receive an email when new articles are posted on . Atsena Therapeutics has dosed the first patient in its open-label, phase 1/2 LIGHTHOUSE study to evaluate the ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. ATSN-201 received orphan drug designation from the FDA ...

DURHAM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, ...

DURHAM, N.C., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent ...

CLEVELAND, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that ...

Atsena Therapeutics Inc.’s IND application for ATSN-201 has been cleared by the FDA enabling the company to initiate a phase I/II trial in patients with X-linked retinoschisis (XLRS) caused by ...

Majority of patients demonstrated successful efficacy readouts across structural measurements (foveal schisis closure) and had meaningful improvement on visual function measurements including MP, BCVA ...